A case of Nivolumab-induced bullous pemphigoid- successfully treated with Rituximab

Authors

• Rawa Amin, Northside Hospital Gwinnett, Lawrenceville, GeorgiaFollow
• Neel Ranpura, Seckinger High School, Buford, Georgia
• Haris Hatic, Suburban Hematology and Oncology Associates, Buford, Georgia

Abstract

Drug-associated bullous pemphigoid (DABP) refers to cases of bullous pemphigoid caused by exposure to various drugs. We present a case of nivolumab (a programmed cell death-ligand 1 (PD-L1) inhibitor) induced bullous pemphigoid in a patient treated for classic Hodgkin’s lymphoma, presenting four months after cessation of therapy. The patient demonstrated minimal clinical response to steroids and methotrexate. Following initiation of rituximab, the patient experienced rapid improvement of the rash with no further disease progression

Recommended Citation

Amin, Rawa; Ranpura, Neel; and Hatic, Haris (2026) "A case of Nivolumab-induced bullous pemphigoid- successfully treated with Rituximab," Journal of Community Hospital Internal Medicine Perspectives: Vol. 16: Iss. 4, Article 23.
DOI: https://doi.org/10.55729/2000-9666.1613
Available at: https://scholarlycommons.gbmc.org/jchimp/vol16/iss4/23

DOI

10.55729/2000-9666.1613